呼吸困难加重可预测肺纤维化进展
该研究关注进行性肺纤维化(PPF)患者,评估基线呼吸困难程度及24周内呼吸困难变化与疾病进展风险的关联。结果显示,基线呼吸困难更重及24周内呼吸困难加重均与疾病进展风险升高相关。
要点
- 基线呼吸困难更重与疾病进展风险升高相关
- 24周内呼吸困难加重与疾病进展风险升高相关
- 呼吸困难变化或可作为肺纤维化进展的监测指标
核心结论
- 在进行性肺纤维化患者中,基线呼吸困难更差及24周内呼吸困难加重均与疾病进展风险增加相关。
研究设计与样本
- 研究设计与样本量原文未报告。
主要发现
- 基线呼吸困难更差与疾病进展风险增加相关。
- 24周内呼吸困难加重与疾病进展风险增加相关。
临床怎么用
- 对进行性肺纤维化患者,可关注基线呼吸困难程度及24周内呼吸困难变化,以辅助识别疾病进展风险较高者。
局限性
- 原文未报告研究设计、样本量及具体效应值,无法评估偏倚风险与结果稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among patients with progressive pulmonary fibrosis, worse dyspnoea at baseline and a worsening of dyspnoea over 24 weeks were associated with an increased risk of disease progression https://bit.ly/3APvQL7 Progressive pulmonary fibrosis (PPF), also known as progressive fibrosing interstitial lung disease (ILD), is a term used to describe progressive lung fibrosis in a patient with an ILD other than idiopathic pulmonary fibrosis (IPF) [1]. Patients with PPF often experience burdensome symptoms such as cough and dyspnoea and impairment in their quality of life [2]. Several studies have reported associations between symptoms and subsequent disease progression in patients with pulmonary fibrosis [3–5], but little is known about the relationship between changes in symptoms and outcomes including survival.
引用
- Wijsenbeek MS, Swigris JJ, Spagnolo P, et al. Worsening dyspnoea as a predictor of progression of pulmonary fibrosis. Eur Respir J. 2024. PMID: 39227075. doi:10.1183/13993003.02211-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。